125 related articles for article (PubMed ID: 16794358)
1. IGF-I and epidermal growth factor levels in follicular fluid of women undergoing controlled ovarian hyperstimulation using the multidose GnRH-antagonist protocol or the long GnRH-agonist protocol.
Asimakopoulos B; Schöpper B; Dawson A; Caglar GS; Vakalopoulos I; Al-Hasani S; Diedrich K; Nikolettos N
J Endocrinol Invest; 2006 May; 29(5):RC5-8. PubMed ID: 16794358
[TBL] [Abstract][Full Text] [Related]
2. Comparison of follicular fluid IGF-I, IGF-II, IGFBP-3, IGFBP-4 and PAPP-A concentrations and their ratios between GnRH agonist and GnRH antagonist protocols for controlled ovarian stimulation in IVF-embryo transfer patients.
Choi YS; Ku SY; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
Hum Reprod; 2006 Aug; 21(8):2015-21. PubMed ID: 16601008
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of follicular levels of sex steroids, gonadotropins and insulin like growth factor-1 (IGF-1) and epidermal growth factor (EGF) in poor responder and normoresponder patients undergoing ovarian stimulation with GnRH antagonist.
Bahceci M; Ulug U; Turan E; Akman MA
Eur J Obstet Gynecol Reprod Biol; 2007 Jan; 130(1):93-8. PubMed ID: 16720073
[TBL] [Abstract][Full Text] [Related]
4. Comparison of preovulatory follicular concentrations of epidermal growth factor, insulin-like growth factor-I, and inhibins A and B in women undergoing assisted conception treatment with gonadotropin-releasing hormone (GnRH) agonists and GnRH antagonists.
Ulug U; Turan E; Tosun SB; Erden HF; Bahceci M
Fertil Steril; 2007 Apr; 87(4):995-8. PubMed ID: 17280662
[TBL] [Abstract][Full Text] [Related]
5. Follicular fluid concentrations of IGF-I, IGF-II, IGFBP-3, VEGF, AMH, and inhibin-B in women undergoing controlled ovarian hyperstimulation using GnRH agonist or GnRH antagonist.
Kaya A; Atabekoglu CS; Kahraman K; Taskin S; Ozmen B; Berker B; Sonmezer M
Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):167-71. PubMed ID: 22776750
[TBL] [Abstract][Full Text] [Related]
6. Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix).
Garcia-Velasco JA; Isaza V; Vidal C; Landazábal A; Remohí J; Simón C; Pellicer A
Hum Reprod; 2001 Dec; 16(12):2533-9. PubMed ID: 11726570
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin-releasing hormone antagonists increase follicular fluid insulin-like growth factor-I and vascular endothelial growth factor during ovarian stimulation cycles.
Ferrari B; Pezzuto A; Barusi L; Coppola F
Gynecol Endocrinol; 2006 Jun; 22(6):289-96. PubMed ID: 16785153
[TBL] [Abstract][Full Text] [Related]
8. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles.
Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY
Fertil Steril; 2008 Apr; 89(4):860-7. PubMed ID: 18249372
[TBL] [Abstract][Full Text] [Related]
9. Levels of apoptosis in human granulosa cells seem to be comparable after therapy with a gonadotropin-releasing hormone agonist or antagonist.
Giampietro F; Sancilio S; Tiboni GM; Rana RA; Di Pietro R
Fertil Steril; 2006 Feb; 85(2):412-9. PubMed ID: 16595220
[TBL] [Abstract][Full Text] [Related]
10. Relationship between ovarian stimulation regimen and cytokine concentration in follicular fluid and their effect on fertilization and pregnancy outcome of patients undergoing ICSI program.
Hammadeh ME; Braemert B; Baltes S; Georg T; Rosenbaum P; Schmidt W
Am J Reprod Immunol; 2000 Jan; 43(1):12-20. PubMed ID: 10698035
[TBL] [Abstract][Full Text] [Related]
11. Concentrations of insulin-like growth factor (IGF)-I and IGF binding protein-3 in the follicular fluid of women undergoing ovarian hyperstimulation with different gonadotropin preparations.
Nardo LG; Bellanca SA; Burrello N; Longo G; D'Agata R; Nardo F; Calogero AE
Gynecol Endocrinol; 2001 Dec; 15(6):413-20. PubMed ID: 11826764
[TBL] [Abstract][Full Text] [Related]
12. Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant follicle-stimulating hormone on follicular fluid levels of adhesion molecules during in vitro fertilization.
Fornaro F; Cobellis L; Mele D; Tassou A; Badolati B; Sorrentino S; De Lucia D; Colacurci N
Fertil Steril; 2007 Jan; 87(1):39-47. PubMed ID: 17084393
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.
Tesarik J; Hazout A; Mendoza-Tesarik R; Mendoza N; Mendoza C
Hum Reprod; 2006 Oct; 21(10):2572-9. PubMed ID: 16926261
[TBL] [Abstract][Full Text] [Related]
14. Comparison of follicular fluid amphiregulin and EGF concentrations in patients undergoing IVF with different stimulation protocols.
Liu N; Ma Y; Li R; Jin H; Li M; Huang X; Feng HL; Qiao J
Endocrine; 2012 Dec; 42(3):708-16. PubMed ID: 22678853
[TBL] [Abstract][Full Text] [Related]
15. Levels of the epidermal growth factor-like peptide amphiregulin in follicular fluid reflect the mode of triggering ovulation: a comparison between gonadotrophin-releasing hormone agonist and urinary human chorionic gonadotrophin.
Humaidan P; Westergaard LG; Mikkelsen AL; Fukuda M; Yding Andersen C
Fertil Steril; 2011 May; 95(6):2034-8. PubMed ID: 21377153
[TBL] [Abstract][Full Text] [Related]
16. GnRH agonist and antagonist protocols for stage I-II endometriosis and endometrioma in in vitro fertilization/intracytoplasmic sperm injection cycles.
Pabuccu R; Onalan G; Kaya C
Fertil Steril; 2007 Oct; 88(4):832-9. PubMed ID: 17428479
[TBL] [Abstract][Full Text] [Related]
17. Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles.
Seow KM; Lin YH; Huang LW; Hsieh BC; Huang SC; Chen CY; Chen PH; Tzeng CR; Hwang JL
Gynecol Endocrinol; 2007 Jun; 23(6):338-42. PubMed ID: 17616858
[TBL] [Abstract][Full Text] [Related]
18. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol.
Orvieto R; Nahum R; Zohav E; Liberty G; Anteby EY; Meltcer S
Gynecol Endocrinol; 2013 Jan; 29(1):51-3. PubMed ID: 22857268
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
[TBL] [Abstract][Full Text] [Related]
20. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
